My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

1.635 -0.015 (-0.91%)
Streaming Delayed Price Updated: 10:20 AM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Autolus Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NASDAQ:SRPT),(NASDAQ:AUTL),(NASDAQ:ARCT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Earnings Scheduled For August 12, 2025
 
Via Benzinga
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Autolus Therapeutics plc
Via GlobeNewswire
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INDP),(NYSE:CATX),(NASDAQ:SLS),(NASDAQ:AUTL EQNX::TICKER_END 
Via FinancialNewsMedia
What 4 Analyst Ratings Have To Say About Autolus Therapeutics
 
Via Benzinga
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Participate in Upcoming Investor Conferences
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens
CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia. 
Via Stocktwits
Topics Artificial Intelligence
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Earnings Scheduled For March 20, 2025
 
Via Benzinga
Autolus Therapeutics to Participate in Upcoming Investor Conferences
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Provides Business Updates and 2025 Overview
From Autolus Therapeutics plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.